INTRODUCTION
Seasonal influenza is a threat to public health with a major socioeconomic impact. 1 Worldwide, influenza is responsible for 3-5 million cases of severe illness and 250,000-500,000 deaths each year, 2 most of which are in high-risk groups, including the elderly (≥65 years), children up to 5 years of age, pregnant women, and people with certain chronic diseases and conditions. [2] [3] [4] [5] [6] Workingage adults are at lower risk of complications, hospitalization, and death than high-risk groups, but they account for approximately one-third of the annual cost of seasonal influenza, mostly due to work absenteeism and reduced productivity. 7, 8 Vaccination is the most cost-effective medical intervention against seasonal influenza.
9,10
The World Health Organization currently recommends that by 2014/15, influenza vaccination coverage should reach 75% in elderly adults and all persons with underlying diseases, 11 targets officially adopted in 2009
by the European Union. 12 In the US, universal influenza vaccination has been recommended for all children ≥6 months of age since 2010. 13 The influenza vaccine coverage, however, remains far below these targets. In European countries, influenza vaccine coverage during the 2006-2007 influenza season ranged from 2%-82% in adults over 65 years of age and from 28%-75% in clinical risk groups. 14 In the US, the most recently reported seasonal influenza coverage rates were 28% in adults 18-49 years of age not at risk, 36% in adults years of age at high risk (ie, with underlying conditions), 45% in adults 50-64 years of age, and 68% in adults 65 years of age and older. 15 Seasonal influenza vaccines have been generally administered by intramuscular (i.m.)
injection. Vaccination by the intradermal (i.d.)
route using a microinjection system has been proposed as a way of improving influenza vaccine uptake because it uses a needle 10 times shorter than the i.m. needle, and because it allows rapid and safe vaccination. 16 Intanza ® /IDflu ® (Sanofi Pasteur SA, Lyon, France), the first microneedle, trivalent, inactivated influenza vaccine, is administered using the Soluvia™ microinjection system (Becton Dickinson, Franklin Lakes, NJ, USA), which consists of a prefilled 0.5 mL glass syringe fitted with a 30-gauge, short-bevel microneedle that protrudes 1.5 mm from a depth-limiting tip.
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The microinjection system also includes a shield that covers the needle after use, preventing needle reuse and accidental needle-stick injuries. 
MATERIALS AND METHODS

Study Design and Participants
This was an uncontrolled, noninterventional, Exclusion criteria included hypersensitivity to the active substances or any of the excipients.
Immunization was postponed in vaccinees with febrile illness or acute infection.
Treatments and Assessments
In the Czech Republic, subjects 18-59 years of 
Statistical Analysis
All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA). 
RESULTS
Intanza/IDflu Vaccinee Responses
A total of 1261 vaccinees completed the survey (Table 1 ). In the Czech Republic, the majority of vaccinees were men, whereas in Turkey, the majority of vaccinees were women.
All 1012 vaccinees in the Czech Republic were vaccinated according to the protocol, whereas 14 of 249 in Turkey were above the age for enrollment (ie, ≥60 years of age, which constituted off-label use of Intanza/IDflu 9 μg) and, therefore, were not vaccinated according to the protocol.
Risk Perception for Contracting Influenza
Most vaccinees in both countries felt at risk of contracting influenza. In the Czech Republic, 66.7% of adults 18-59 years of age and 89.2%
of elderly adults felt at risk, whilst in Turkey, 90.3% felt at risk (Table 2 ). In Turkish and Czech 
Frequency of Vaccination
In reported that they had not been previously vaccinated for seasonal influenza (Table 2 ).
In addition, just over half of those previously vaccinated (57.1%) had been vaccinated the year before.
Main Reasons for Being Vaccinated
In both Turkey and the Czech Republic, the most common reason prompting vaccination, cited by more than half of the vaccinees, was the advice of a physician (Table 2) 
Main Reasons for Missing Vaccination
In Turkey, the most common reason for missing previous vaccinations was "I was not encouraged to be vaccinated" ( 
